Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

NIAID-backed COVID-19 trial to investigate monoclonal antibodies from Brii Biosciences

By Brian Buntz | January 6, 2021

Brii BiosciencesMonoclonal antibodies could play a vital role in the battle against COVID-19. To date, such infusion-delivered antibodies from Eli Lilly (NYSE:LLY) and Regeneron Pharmaceuticals (NSDQ:REGN) have received emergency use authorization from FDA. 

Now, a phase 2/3 clinical trial will study the potential of investigational monoclonal antibody therapy for patients with mild-to-moderate COVID-19. 

The antibodies, known as BRII-196 and BRII-198, are licensed to Brii Biosciences, a Beijing-based company. Phase 1 trials for COVID-19 infections commenced in July 2020. 

The National Institute of Allergy and Infectious Diseases (NIAID) will sponsor the phase 2/3 trial as part of the ACTIV-2 master protocol, which is assessing the potential of several experimental therapies to treat mild-to-moderate COVID-19. The ACTIV-2 trial began in August 2020 with an investigation of another monoclonal antibody, LY-CoV555, from Lilly and AbCellera Biologics (NSDQ:ABCL). 

The NIAID-backed AIDS Clinical Trials Group will lead the trial, which will initially enroll 220 participants internationally. Half of those volunteers will receive placebo infusions.  

An independent Data and Safety Monitoring Board (DSMB) can authorize the transition to a Phase 3 trial if the antibodies meet safety and efficacy endpoints. 

 

Tell Us What You Think! Cancel reply

Related Articles Read More >

COVID-19 vaccine
Is there a link between Bell’s palsy and COVID-19 vaccines?
Johnson & Johnson
FDA authorizes J&J’s single-dose COVID-19 vaccine
Health Canada AstraZeneca Canada COVID-19 vaccine
Health Canada authorizes AstraZeneca’s COVID-19 vaccine
Johnson & Johnson
8 things to keep in mind related to the FDA advisory meeting on J&J vaccine

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards